Xenetic Biosciences Inc (XBIO) News & EventsXBIOXenetic Biosciences Inc

Xenetic Biosciences Collaborates with PeriNess on Clinical Study

Xenetic Biosciences announced that its collaboration partner, PeriNess, has informed the Company that the first patient has been dosed in an investigator-initiated clinical study evaluating systemic recombinant human DNase in combination with anti-CD19 CAR T-cell therapy in patients with large B-cell lymphoma at the Tel Aviv Sourasky University Medical Center in Israel. The milestone marks the first clinical evaluation of Xenetic's systemic DNase technology as an adjunct to CAR T-cell therapy. The study, sponsored by the Ichilov Center, was approved by the Israeli Ministry of Health and the applicable Institutional Review Board in June 2026 and is designed to evaluate whether degradation of cell-free chromatin and neutrophil extracellular traps can improve CAR T-cell expansion, persistence and clinical response. The study is enrolling 12 patients with LBCL who have stable or progressive disease prior to lymphodepletion therapy, a population with a historically poor prognosis and one-year progression-free survival of approximately 20% to 30%. Patients will receive a commercial anti-CD19 CAR T-cell product, tisagenlecleucel, axicabtagene ciloleucel or lisocabtagene maraleucel, in combination with DNase I administered as a 50 mL intravenous infusion at 1.0 mg/kg on Days 0, 3, 6, 10 and 15 following CAR T-cell infusion. Clinical efficacy will be evaluated by objective response rate at one and three months following CAR T-cell infusion, duration of response, disease control rate and overall survival at 12 months. The study also includes a translational component designed to assess biomarker response, including circulating cell-free DNA and NET markers, as well as anti-CD19 CAR T-cell expansion and persistence.

Xenetic Biosciences to Acquire Santersus

Xenetic Biosciences and Santersus announced that they have entered into a definitive share exchange agreement pursuant to which Xenetic will, subject to stockholder approval, acquire all of the outstanding share capital of Santersus in exchange for newly issued shares of Xenetic in an all-stock transaction. The combined company is expected to continue to trade on the Nasdaq Capital Market as Santersus Bio, under new ticker symbol "SNTS." The Proposed Transaction is expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on a single high-impact therapeutic target: neutrophil extracellular traps, or NETs.

Xenetic Biosciences and PeriNess Receive Israeli Health Ministry Approval for Clinical Study

Xenetic Biosciences announced that its collaboration partner, PeriNess, has informed the Company that it received formal approval from the Israeli Ministry of Health and the respective Institutional Review Board to conduct an exploratory clinical study of a combination systemic DNase I with anti-CD19 CAR T Cells in large B cell lymphoma patients. This approval follows preclinical results that demonstrated significant improvement of CAR T cell expansion and persistence and functionality when combined with DNase I. This combination therapy resulted in improved tumor control, delayed relapse and prolonged survival across multiple preclinical models of leukemia and lymphoma. Under the approved clinical study protocol, 12 LBCL patients with stable or progressive disease prior to lymphodepletion therapy are intended to be treated with CAR T cells targeting CD19 in combination with DNase I. Clinical efficacy is intended to be evaluated by the Objective Response Rate at 1 and 3 months post CAR T infusion, duration of response, disease control rate and overall survival at 12 months post CAR T cells infusion. Ron Ram, Professor of Medicine and Head of the Bone Marrow Transplantation Unit at the Sourasky Center, has initiated the study as the principal investigator and all work is intended to be conducted at Sourasky Center in Israel.